Kynam Capital Reports 15.0M Shares (6.90%) in CytomX

CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang filed an Amendment No. 1 to a Schedule 13G/A reporting 15,013,093 shares of Common Stock, representing 6.90% of the class.

Rhea-AI Filing Summary

CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang filed an Amendment No. 1 to a Schedule 13G/A reporting 15,013,093 shares of Common Stock, representing 6.90% of the class.

The filing lists shared voting and dispositive power over the reported 15,013,093 shares. Signatures show the filing was executed on 05/15/2026.

Insights

Institutional Ownership Analyst

Large passive stake disclosed: 15,013,093 shares (6.90%).

The filing shows Kynam Capital Management and affiliated entities report beneficial ownership of 15,013,093 shares with shared voting and dispositive power. The ownership is disclosed on an amended Schedule 13G/A, consistent with passive institutional reporting.

Cash‑flow treatment and any trading intentions are not stated; subsequent filings would disclose changes in voting or disposition if they occur.

Key Figures

Filing type: Schedule 13G/A (Amendment No. 1) Beneficial ownership: 15,013,093 shares Percent of class: 6.90%

3 metrics

Filing type Schedule 13G/A (Amendment No. 1) Amendment reporting beneficial ownership

Beneficial ownership 15,013,093 shares Amount reported in Item 4(a)

Percent of class 6.90% Percent reported in Item 4(b)

Key Terms

Beneficially owned, Shared dispositive power, Schedule 13G/A

3 terms

Beneficially owned regulatory

"Item 4. | Ownership (a) | Amount beneficially owned: 15,013,093"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Item 4. | (iv) Shared power to dispose or to direct the disposition of: 15,013,093"

Schedule 13G/A regulatory

"(Amendment No. 1 ) ... Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Kynam Capital report in CTMX?

Kynam Capital and affiliated filers report beneficial ownership of 15,013,093 shares, representing 6.90% of CytomX Therapeutics' common stock. The filing attributes shared voting and dispositive power over those shares to the named filers.

Which entities are named on the Schedule 13G/A for CTMX?

The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and individual Yue Tang. All three are listed as having shared voting and shared dispositive power over the reported 15,013,093 shares.

When was the Schedule 13G/A amendment signed?

Signatures on the amendment show execution on 05/15/2026. The header of the filing also references 03/31/2026 in the document; the amendment bears the later signature dates.

Does the filing indicate Kynam will sell or buy CTMX shares?

The Schedule 13G/A lists ownership and voting/dispositive power but does not state any intent to buy or sell. The amendment reports current beneficial ownership; trading intentions are not disclosed in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:01 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

23284F105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23284F105

1

Names of Reporting Persons

Kynam Capital Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,013,093.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,013,093.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 23284F105

1

Names of Reporting Persons

Kynam Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,013,093.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,013,093.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 23284F105

1

Names of Reporting Persons

Yue Tang

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,013,093.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,013,093.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytomX Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CALIFORNIA 94080
Item 2.
(a)	Name of person filing: Kynam Capital Management, LP Kynam Capital Management GP, LLC Yue Tang
(b)	Address or principal business office or, if none, residence: 221 ELM ROAD PRINCETON, New Jersey 08540
(c)	Citizenship: Kynam Capital Management, LP - DELAWARE Kynam Capital Management GP, LLC - DELAWARE Yue Tang - UNITED STATES
(d)	Title of class of securities: Common Stock, $0.00001 par value per share
(e)	CUSIP No.: 23284F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15,013,093
(b)	Percent of class: 6.90 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(ii) Shared power to vote or to direct the vote: Kynam Capital Management, LP - 15,013,093 Kynam Capital Management GP, LLC - 15,013,093 Yue Tang - 15,013,093
	(iii) Sole power to dispose or to direct the disposition of: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(iv) Shared power to dispose or to direct the disposition of: Kynam Capital Management, LP - 15,013,093 Kynam Capital Management GP, LLC - 15,013,093 Yue Tang - 15,013,093
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kynam Capital Management, LP

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	05/15/2026

Kynam Capital Management GP, LLC

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	05/15/2026

Yue Tang

Signature:	Yue Tang
Name/Title:	Self
Date:	05/15/2026